Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Clinical trial NCT05263050 · RECRUITING

Trial details

NCT number: NCT05263050
Sponsor: Fox Chase Cancer Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Renal Cell Carcinoma Clear-cell Metastatic Renal Cell Carcinoma Neuroendocrine Tumors Carcinoid Tumor

Start date: 2022-01-21
Primary completion: 2026-12-01
Enrollment: 111

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.